A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component

Journal of Thoracic Oncology

Volumn 9, Issue 12, 2014, Pages 1772-1778

  Zhang, Yang ^a,b   Wang, Rui ^a,b   Cai, Deng ^a,b   Li, Yuan ^a,b   Pan, Yunjian ^a,b   Hu, Haichuan ^a,b   Wang, Lei ^a,b   Li, Hang ^a,b   Ye, Ting ^a,b   Luo, Xiaoyang ^a,b   Zhang, Yiliang ^a,b   Li, Bin ^a,b   Shen, Lei ^a,b   Sun, Yihua ^a,b   Chen, Haiquan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Driver mutations; Lung adenocarcinoma; Micropapillary pattern; Prognosis

Indexed keywords

ERLOTINIB; GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; BRAF GENE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; EGFR GENE; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HER2 GENE; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROPAPILLARY COMPONENT LUNG ADENOCARCINOMA; MICROPAPILLARY PREDOMINANT LUNG ADENOCARCINOMA; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RET GENE; ROS1 GENE; STATISTICAL ANALYSIS; TREATMENT RESPONSE; ADENOCARCINOMA; ANIMAL; LUNG TUMOR; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PROGNOSIS; SURVIVAL; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE, NUDE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84927694681     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000341     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-299.
3. Bronte G, Rizzo S, La Paglia L, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010;36:S21-S29.
4. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
5. Zhang Y, Sun Y, Pan Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012;18:1947-1953.
6. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer 2013;81:371-376.
7. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013;8:52-61.
8. Warth A, Penzel R, Lindenmaier H, et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J 2014;43:872-883.
9. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664.
10. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438-1446.
11. Roh MS, Lee JI, Choi PJ, Hong YS. Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma. Histopathology 2004;45:580-586.
12. Kawakami T, Nabeshima K, Hamasaki M, Iwasaki A, Shirakusa T, Iwasaki H. Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas. Virchows Arch 2009;454:61-70.
13. Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 2013;258:1079-1086.
14. Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl Cancer Inst 2013;105:1212-1220.
15. Campos-Parra AD, Avilés A, Contreras-Reyes S, et al. Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. Eur Respir J 2014;43:1439-1447.
16. Westaway DD, Toon CW, Farzin M, et al. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology 2013;45:553-558.
17. Russell PA, Barnett SA, Walkiewicz M, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol 2013;8:461-468.
18. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-271.
19. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 2014;84:121-126.
20. Zhang J, Wu J, Tan Q, Zhu L, Gao W. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol 2013;8:1196-1202.
21. Sumiyoshi S, Yoshizawa A, Sonobe M, et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer 2013;81:53-59.
22. Zhang J, Liang Z, Gao J, Luo Y, Liu T. Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology 2011;59:1204-1214.
23. Tsutsumida H, Nomoto M, Goto M, et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol 2007;20:638-647.
24. Miyoshi T, Shirakusa T, Ishikawa Y, et al. Possible mechanism of metastasis in lung adenocarcinomas with a micropapillary pattern. Pathol Int 2005;55:419-424.
25. Hoshi R, Tsuzuku M, Horai T, Ishikawa Y, Satoh Y. Micropapillary clusters in early-stage lung adenocarcinomas: a distinct cytologic sign of significantly poor prognosis. Cancer 2004;102:81-86.
26. De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 2009;131:694-700.